Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Impax Reports Second Quarter 2016 Financial Results
August 9, 2016 7:01 AM EDTHAYWARD, Calif., Aug. 9, 2016 /PRNewswire/ --Â Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported second quarter 2016 financial results for the quarter ended June 30, 2016.
Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO
Total revenues in the second quarter 2016 declined 19% to $172.6 million, compared to $214.2 million in the prior year period. The decrease was primarily due to a 30% reduction in Generics division revenues which includes the impact of an approximate... More